within Pharmacolibrary.Drugs.ATC.A;

model A16AB09
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.8333333333333334e-05,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00027,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0036,
    k12             = 11.9,
    k21             = 11.9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A16AB09</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Idursulfase is a recombinant enzyme replacement therapy used for the treatment of Hunter syndrome (mucopolysaccharidosis II), a rare lysosomal storage disorder caused by a deficiency of the enzyme iduronate-2-sulfatase. The drug is approved for use in patients with this genetic condition and is administered via intravenous infusion.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on data from male pediatric and adult patients with Hunter syndrome (MPS II) receiving 0.5 mg/kg intravenous infusions of idursulfase once weekly.</p><h4>References</h4><ol><li><p>Xie, H, et al., &amp; McCauley, TG (2015). Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration. <i>PloS one</i> 10(4) e0122453–None. DOI:<a href=\"https://doi.org/10.1371/journal.pone.0122453\">10.1371/journal.pone.0122453</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25836678/\">https://pubmed.ncbi.nlm.nih.gov/25836678</a></p></li><li><p>Whiteman, DA, &amp; Kimura, A (2017). Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future. <i>Drug design, development and therapy</i> 11 2467–2480. DOI:<a href=\"https://doi.org/10.2147/DDDT.S139601\">10.2147/DDDT.S139601</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28860717/\">https://pubmed.ncbi.nlm.nih.gov/28860717</a></p></li><li><p>Muenzer, J, et al., &amp; Alexanderian, D (2022). Long-term open-label phase I/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II. <i>Genetics in medicine : official journal of the American College of Medical Genetics</i> 24(7) 1437–1448. DOI:<a href=\"https://doi.org/10.1016/j.gim.2022.04.002\">10.1016/j.gim.2022.04.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35588317/\">https://pubmed.ncbi.nlm.nih.gov/35588317</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A16AB09;
